Tissue-Based Diagnostic Biomarkers of Aggressive Variant Prostate Cancer: A Narrative Review
Cancers · 16.02.2024 · 16 (4) · 805
DOI: 10.3390/cancers16040805 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 16.02.2024. Verfasst von Olga Kouroukli und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Evaggelismos General Hospital, 10676 Athens, Greece. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 191 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ronald and Rita McAulay Foundation.
Abstract (Originalsprache)
Prostate cancer (PC) is a common malignancy among elderly men, characterized by great heterogeneity in its clinical course, ranging from an indolent to a highly aggressive disease. The aggressive variant of prostate cancer (AVPC) clinically shows an atypical pattern of disease progression, similar to that of small cell PC (SCPC), and also shares the chemo-responsiveness of SCPC. The term AVPC does not describe a specific histologic subtype of PC but rather the group of tumors that, irrespective of morphology, show an aggressive clinical course, dictated by androgen receptor (AR) indifference. AR indifference represents an adaptive response to androgen deprivation therapy (ADT), driven by epithelial plasticity, an inherent ability of tumor cells to adapt to their environment by changing their phenotypic characteristics in a bi-directional way. The molecular profile of AVPC entails combined alterations in the tumor suppressor genes retinoblastoma protein 1 (RB1), tumor protein 53 (TP53), and phosphatase and tensin homolog (PTEN). The understanding of the biologic heterogeneity of castration-resistant PC (CRPC) and the need to identify the subset of patients that would potentially benefit from specific therapies necessitate the development of prognostic and predictive biomarkers. This review aims to discuss the possible pathophysiologic mechanisms of AVPC development and the potential use of emerging tissue-based biomarkers in clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Evaggelismos General Hospital, 10676 Athens, Greece.
- Department of Anatomy-Histology-Embryology, School of Medicine, University of Patras, 26504 Patras, Greece.
- Department of Urology, School of Medicine, University of Patras, 26504 Patras, Greece.
- Department of Pathology, School of Medicine, University of Patras, 26504 Patras, Greece.
ORCID-Profile: Olga Kouroukli, Vasiliki Bravou, Vasiliki Tzelepi
Förderung
- Ronald and Rita McAulay Foundation
Zitieren
APA
Kouroukli, O., Bravou, V., Giannitsas, K., & Tzelepi, V. (2024). Tissue-Based Diagnostic Biomarkers of Aggressive Variant Prostate Cancer: A Narrative Review. Cancers, 16(4), 805. https://doi.org/10.3390/cancers16040805
Vancouver
Kouroukli O, Bravou V, Giannitsas K, Tzelepi V. Tissue-Based Diagnostic Biomarkers of Aggressive Variant Prostate Cancer: A Narrative Review. Cancers. 2024;16(4):805. doi:10.3390/cancers16040805
BibTeX
@article{Kouroukli2024,
author = {Kouroukli, Olga and Bravou, Vasiliki and Giannitsas, Konstantinos and Tzelepi, Vasiliki},
title = {Tissue-Based Diagnostic Biomarkers of Aggressive Variant Prostate Cancer: A Narrative Review},
journal = {Cancers},
year = {2024},
volume = {16},
number = {4},
pages = {805},
doi = {10.3390/cancers16040805}
}
EUVIMED